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 An adaptive design to bridge the gap between 
Phase 2b/3 microbicide effectiveness trials and 
evidence required for licensure 
 Douglas J  Taylor a  ,  Anneke  Grobler b  and  Salim S  Abdool Karim b,c  
Background Vaginally and rectally applied microbicides are being developed to 
help prevent sexual acquisition of HIV. Due to the lack of surrogate outcomes, the 
path toward licensure typically moves directly from expanded safety studies to 
expensive Phase 2b/3 trials with rare incident infection outcomes. The need to con-
firm an initial trial’s significant finding can lead to serious delays in implementing 
essential programs to reduce the spread of HIV. 
Purpose To propose an adaptive design where a Phase 2b/3 study powered to 
detect a clinically meaningful effect with evidence of one trial (observing one-sided 
p < 0.025) is allowed to expand by a prespecified, feasible amount if interim data 
suggest the chance of further achieving a more robust evidence threshold ( p < 
0.001, potentially sufficient for licensure from a single trial) is promising. 
 Methods As an example, prespecified conditional power criteria are used to deter-
mine whether a 90-event trial with 90% power to detect a 50% reduction in risk 
should be expanded to 130 events. Asymptotic results and simulations are used to 
assess false-positive error rates and other operating characteristics of the design. 
 Results False-positive error rates can be controlled at the desired 0.025 and 0.001 
levels with appropriate choice of critical values or expansion criteria. The chance of 
achieving robust evidence can approach that of a 130-event trial with traditional 
stopping boundaries (controlling  a = 0.001) but with substantially lower expected 
size for plausible effectiveness levels. 
 Limitations Conditional power calculations assume the interim estimate of effect is 
an unbiased estimate for the remainder of the trial, an assumption which may not 
hold if product adherence varies over time. Observing a measure of effect with  p < 
0.001 may not be sufficient for licensure. A decision to expand the trial would be 
informative to investigators regarding the interim effect size. 
Conclusions A moderate increase in trial size can make the difference between a 
study with good power to detect a clinically meaningful effect and one which may 
reasonably obtain the robust evidence required for regulatory bodies and public 
health programs to consider making a new microbicide available to persons at risk 
of HIV infection. The proposed design allows for this possibility while not requiring 
investigators to make an up-front commitment to a prohibitively large trial.  Clinical 
Trials 2012;  9 : 377–384. http://ctj.sagepub.com 
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Introduction
An estimated 33.4 million people were living with 
HIV in 2008 [1], with the majority of infections 
acquired through sexual intercourse. Microbicides 
are vaginally or rectally administered products such 
as antiretroviral-based gels and rings being devel-
oped to protect individuals from infection. A major 
challenge facing microbicide researchers is the 
absence of surrogate endpoints to inform effective-
ness in modest-sized Phase 2 trials. As a result, prod-
uct development typically moves from safety studies 
to large and expensive Phase 2b/3 trials with rare 
incident infection outcomes. Related challenges 
include the possibility that participants are exposed 
to HIV through unprotected routes (e.g., rectal 
exposure in a vaginal gel study [2,3]) and the 
dependence of effectiveness on unobserved adher-
ence [4]. As a consequence, determining plausible 
effectiveness levels to inform the size of Phase 2b/3 
trials is extremely challenging.
Investigators typically specify a clinically or pro-
grammatically meaningful effect for use in power 
calculations, such as a 50% reduction in risk. 
Randomizing participants to test or placebo in equal 
numbers and following them until 90 infections 
have been observed provides approximately 90% 
power to detect such an effect at the one-sided a = 
0.025 level of significance under standard propor-
tional hazards assumptions. The chance of failing to 
achieve a statistically significant result will be 
greater than 10% if the product is less than 50% 
effective, but this is implicitly acceptable on the 
grounds that smaller effect sizes are not necessarily 
meaningful for public health program implementa-
tion. If the microbicide were actually 65% effective, 
then the same trial would have greater than 99% 
power to achieve a statistically significant result, 
potentially representing an excessive use of limited 
resources. Incorporating appropriate interim moni-
toring (IM) procedures provides protection against 
this scenario while controlling Type I error at the 
desired level [5].
Standard practice dictates that a significant find-
ing in a Phase 3 study be confirmed in a second trial 
before a new drug can be licensed. Fleming and 
Richardson [6] noted, however, that it could be dif-
ficult to justify such replication for preventing an 
outcome associated with high morbidity or mortal-
ity like HIV. Furthermore, the US Food and Drug 
Administration has expressed their willingness to 
consider the results of a single, well-conducted trial 
for licensure of a microbicide if the observed strength 
of evidence is comparable to that obtained from two 
independent trials, each with Type I error a = 0.025 
[7]. This is generally interpreted to mean observing 
a one-sided p-value less than about 0.001 (recogniz-
ing that the chance of making false-positive errors 
in two traditional Phase 3 trials is 0.025 × 0.025 = 
0.000625). With this in mind, investigators may 
consider implementing a large Phase 3 trial with a = 
0.001 in hopes of accelerating the development pro-
cess. Returning to the previous example, a study 
with 170 events would be required to achieve 90% 
power to detect a 50% reduction in risk with a = 
0.001. Given that obtaining 170 events would neces-
sitate planning for nearly 8000 person-years of 
intense follow-up if the incidence rate in the control 
group is 0.03 (not an atypical assumption), under-
taking such an expensive study would be imprudent 
without preliminary evidence of effectiveness.
Fleming and Richardson [6] proposed a Phase 2b 
screening trial for this setting, whereby a study with 
a third to a fourth as many events as required for 
the large Phase 3 is initially conducted. The results 
of the screening trial inform whether further testing 
of the product should be undertaken and if so, how 
large the subsequent trial should be to achieve the 
robust strength of evidence required for licensure. 
In our example, a Phase 2b screening trial would 
accumulate 45–55 HIV events. This smaller trial still 
has 90% chance of obtaining robust evidence (p < 
0.001) if the product is actually 75% effective. On 
the other hand, the screening trial is underpowered 
(60%–70%) to detect the meaningful 50% effect 
with evidence of one trial (p < 0.025), and observing 
a promising yet nonsignificant result could still 
require that a large Phase 3 trial be conducted. 
Gilbert [8] contrasted the Phase 2b screening trial 
design with traditional Phase 3 designs in the con-
text of HIV vaccine trials by comparing their 
expected utility.
The use of p-values and tests of significance to 
infer strength of evidence is the subject of long-
standing debate [9]. Nonetheless, they remain inte-
gral to the processes of drug development and public 
health policy decision making. With this in mind, 
we consider another alternative to large Phase 3 tri-
als, one that is also grounded in the use of p-values 
and significance tests to infer strength of evidence. 
We describe an adaptive design where a study with 
high power to detect a prespecified and meaningful 
effect size with evidence of one trial (observing p < 
0.025) expands by a prespecified amount if interim 
data suggest that there is a reasonable chance of 
achieving a robust evidence threshold (p < 0.001; 
potentially sufficient for licensure). Such a situation 
could occur if the true effectiveness of the microbi-
cide is modestly greater than the meaningful effect 
size specified when designing the study.
Using the proposed design, a trial could be 
declared a success at one of two different strengths 
of evidence; p < 0.025 or p < 0.001. This is concep-
tually similar to studies designed to achieve either 
a claim of superiority or noninferiority, depend-
ing, for example, on whether a confidence interval 
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(CI) for the hazard ratio excludes 1 or a larger but 
prespecified noninferiority margin. The approach 
has parallels to adaptive monitoring and other 
flexible sample size procedures in which an interim 
estimate of effect is used to determine final sample 
size when no clinically meaningful effect is speci-
fied in advance [10,11]; even without adjustment 
to the critical value, expanding a trial when the 
interim data are sufficiently promising will not 
inflate the Type I error for a fixed level-a test [12]. 
Although similar in idea, the proposed design dif-
fers from these methods in that the purpose for 
adapting the trial is to improve the chance of 
achieving a second evidence threshold, rather than 
to achieve a target power for a fixed level-a test; 
the concept of a clinically meaningful effect is 
maintained; and only one formal test of effective-
ness must take place, the timing of which is deter-
mined by interim data. The fact that repeat testing 
is not required with the proposed design may alle-
viate efficiency concerns raised for some adaptive 
monitoring procedures [13,14]. Finally, the 
approach is similar to a Phase 2 trial that rolls 
directly into a large Phase 3 with a = 0.001 [6]. 
Here, however, there is no consideration to imple-
ment such a large study, and achieving evidence of 
one trial (p < 0.025) remains key.
A hypothetical example is used to motivate the 
proposed trial design. Methods of assessing the 
operating characteristics of the design (e.g., false-
positive error rates, chance of achieving various 
strengths of evidence, and bias of treatment effect 
estimators) and a comparison of its performance to 
that of more traditional designs are explored using 
asymptotic methods and simulation studies. This is 
followed by an example where the adaptive design 
was considered when planning a microbicide trial, 
and a discussion of limitations and conclusions.
Trial design
The proposed adaptive design requires specifying the 
numbers of events at which interim and final analy-
ses do, or potentially could, take place, as follows:
NIA: the number of events that triggers an interim 
assessment of effectiveness;
N1: the number of events needed to achieve a desired 
power to detect a meaningful effect with strength of 
evidence of one trial (p < 0.025);
N*: the largest number of events that the investiga-
tor deems prudent and feasible; and
N2: the number of events needed to achieve a desired 
power to detect a meaningful effect with strength of 
evidence of two trials (p < 0.001).
Only scenarios where N* < N2 are considered in this 
article. Besides these event counts, the criteria for 
expanding from N1 to N* must be prespecified. This 
is done recognizing that if the interim estimate of 
effectiveness (EIA) is too small, then the conditional 
power to achieve robust evidence will be insuffi-
cient to warrant expansion. Likewise, if EIA is large, 
then the chance of achieving robust evidence will 
be high without the need for expansion. The range 
for EIA which triggers expansion is denoted (EL, EU). 
The wider the range, the more likely expansion is to 
take place and the more the adaptive design will 
behave like a fixed event trial of size N*. Thus, the 
probability of trial expansion is a critical operating 
characteristic.
To place the design in context, consider the exam-
ple depicted in Figure 1 where investigators deter-
mine that a 50% risk reduction is clinically and 
programmatically meaningful. Here, N1 = 90 events 
and N2 = 170 events provide a 90% chance of observ-
ing p < 0.025 and p < 0.001, respectively, but launch-
ing into the larger trial is not warranted without 
preliminary evidence of effectiveness. However, 130 
events provide a 90% chance of observing p < 0.001 if 
the microbicide is 55% effective, just 5% greater than 
the 50% meaningful effect. The investigators deter-
mine that N* = 130 is feasible and are open to trial 
expansion if the interim data are persuasive. Values 
for NIA and (EL, EU) are then prespecified based on 
false-positive error rate, conditional power, and oper-
ational considerations discussed in the following.
Operating characteristics of the 
proposed adaptive design
False-positive error rates
We assess false-positive error rates by considering 
the following test statistic for comparing survival 













NIA < 90 events
Expand to N* = 130 Continue to N1 = 90
Estimate effect, EIA
EL ≤  EIA ≤ EU EIA < EL or EIA > EU
Figure 1. Illustrative adaptive design.
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Here, HRj is the estimated hazard ratio (test vs. con-
trol) obtained from a Cox’s proportional hazards 
regression model after j events have been observed. 
Asymptotically, Zj is distributed normal with mean 
zero and variance one under the null hypothesis of 
no treatment effect if standard assumptions (e.g., 
no informative censoring) are met. Normality does 
not hold, however, when the final event size is cho-
sen conditional on an interim estimate of effective-
ness. In particular, the proposed design dictates that 
the trial expand from N = N1 to N = N* events if (EL 
≤ EIA ≤ EU), where EIA = 1 − HRIA. Large sample false-
positive error rates in this scenario equal
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where z(∙) is the standard normal density, 
(1 ) /4; ( , )lnt E N i L Ui i IA != - , and { | }Pr Z z Zj p NIA1  is 
the conditional probability that the final test statis-
tic falls below the pth percentile of a standard nor-
mal variable, zp (see Appendix 1 for an asymptotic 
expression of this probability).
It is apparent from Equation (2) that choosing 
zp = za will not in general provide a size a test; false-
positive error rates can be inflated or deflated, 
depending on the choice of NIA and (EL, EU). Since 
Equation (2) is an increasing function of zp, how-
ever, an asymptotically unbiased test can be 
obtained by solving for p such that the false-positive 
error rate equals a. In order to understand the 
potential magnitude of bias when letting zp = za, 
false-positive error rates for the motivating example 
in Figure 1 were computed for nominal ad {0.025, 
0.001}, all NIA < N1 and (EL, EU) d {(0.01, 0.02), (0.01, 
0.03), …, (0.01, 0.99), …, (0.98, 0.99)}. Equation (2) 
was solved using the QUAD function in SAS/IML® 
[15] to perform the required numerical integration 
or a simple trapezoidal rule if the function failed to 
converge.
Some of the evaluated NIA and (EL, EU) make no 
practical sense (e.g., NIA = 1) and others would rep-
resent obvious attempts to inflate the false-positive 
error rate. Nonetheless, the bias was generally mod-
est over the comprehensive range of assessed condi-
tions, with realized error rates between 0.014 and 
0.036 for a nominal a = 0.025 level test and between 
0.0004 and 0.0016 for a nominal a = 0.001 level test. 
Maximum and minimum error rates occur when 
NIA = 89 and information regarding the likely out-
come after N1 = 90 events is greatest. As extreme 
examples, choosing (EL, EU) such that expansion 
must occur if the conditional probability of rejec-
tion is essentially zero without expansion will inflate 
the error rates. Likewise, choosing (EL, EU) such that 
expansion must occur if the chance of rejection is 
already 100% will deflate the error rates. As exempli-
fied below, however, the absolute bias may be neg-
ligible for reasonable choice of expansion criteria 
(akin to the fact that the false-positive error rate for 
a fixed level-a test need not be inflated when sample 
size is increased based on interim data [12]).
Power considerations
Building on the asymptotic results in the previous 
section, simulation studies were used to assess the 
chance of achieving the desired strengths of evi-
dence under null and alternative hypotheses in 
finite samples. There are infinitely many combina-
tions of NIA and (EL, EU) which could be considered 
for the example in Figure 1, and any attempt to 
optimize their selection needs to balance power 
and the chance of trial expansion for a range of 
plausible effect sizes against the willingness of 
investigators to invest in a larger trial under those 
scenarios. Recognizing the inherent subjectivity of 
such an exercise, data were simulated under the 
assumption that the interim analysis takes place 
after either NIA = 60 or 89 events; NIA = 60 represent-
ing a practical choice in that investigators might 
want appreciable time between the interim analysis 
and the expected date of the 90th event to plan for 
expansion, and NIA = 89 representing the maximum 
possible information to inform the decision to 
expand. Next, values of (EL, EU) were chosen such 
that the trial would expand from N1 = 90 events to 
N* = 130 events if the conditional power to achieve 
robust evidence (p < 0.001) under expansion is at 
least 50% and the conditional power in the absence 
of expansion is less than 95%. Using formulae pre-
sented in Appendix 1, and assuming the true haz-
ard ratio equals HRIA, we obtain (EL, EU) = (0.418, 
0.573) when NIA = 60 and (EL, EU) = (0.418, 0.497) 
when NIA = 89. Although not optimized in any for-
mal sense, these criteria for expansion are consist-
ent with the motivation for the proposed design; 
expand if there is a reasonable chance of obtaining 
robust evidence of effect, unless the chance is 
already very high without expansion.
Simulated data were generated under an expo-
nential failure time distribution for a range of true 
hazard ratios between 0.3 and 0.9 (i.e., between 
70% and 10% effectiveness), as well as the null case. 
For each simulated condition, 10,000 replicates of 
data (50,000 for the null case) were generated and 
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analyzed using proportional hazards regression in 
SAS®, assuming 90% censoring at 1 year in the con-
trol group. Probabilities of achieving p < 0.025 and 
p < 0.001, respectively, were estimated based on the 
proportion of replicates for which upper one-sided 
97.5% and 99.9% confidence bounds for the hazard 
ratio excluded 1.0 (nominal coverage rates were 
used since numerical evaluation of equation (2) 
determined that false-positive error rates are well 
controlled in these scenarios: 0.0220 and 0.00084, 
respectively, for a = 0.025 and a = 0.001 level tests 
when NIA = 60; 0.0237 and 0.0010 when NIA = 89). 
The costs and benefits associated with the design 
are summarized in terms of the probability that trial 
expansion occurs as a function of effectiveness, as 
well as the chance of observing p < 0.001 given that 
expansion takes place.
In order to compare the operating characteristics 
of the adaptive trial to more traditional designs, 
false-positive error rates and power of fixed N = 
90-event and N = 130-event trials were computed. 
Likewise, power was computed for a trial with IM 
based on the Lan–DeMets spending function [16] 
with O’Brien–Fleming-type stopping boundaries 
[17] (computed in East® [18]) to control the false-
positive error rate at a = 0.001, assuming interim 
analyses occur after 60 and 90 events and maximum 
trial information of Nmax = 130.
Bias of estimated treatment effects
An additional concern when implementing a trial 
which allows for early stopping is the potential bias 
of estimated treatment effects, since this can impact 
the interpretation of study results. Unconditional 
bias for the adaptive design in Figure 1 (with NIA = 
60, N1 = 90, and N* = 130) was estimated based on 
the mean of the simulated HR estimates, regardless 
of whether or not expansion took place. For com-
parison, bias was also summarized for a trial that 
incorporates O’Brien–Fleming-type stopping 
boundaries with Nmax = 130 and interim analyses 
after 60 and 90 events.
Simulation results
False-positive error rates and power
As expected, the estimated false-positive error rates are 
near, but do not exceed, the nominal 0.025 and 0.001 
levels for the example adaptive design (Table 1), 
emphasizing that test size may be well controlled 
when using unadjusted critical values. The chance 
that a traditional trial using O’Brien–Fleming-type 
stopping boundaries achieves p < 0.025 is essentially 
identical to that of a fixed N = 130-event trial for 
all evaluated effect sizes (results not shown). In 
contrast, power of the adaptive design to observe p 
< 0.025 is essentially the same as a fixed 90-event 
trial, regardless of whether the interim analysis 
takes place after NIA = 60 or 89 events (Figure 2). 
Given that the purpose of the adaptive design is to 
increase the chance of achieving robust evidence of 
effect, however, the chance of observing p < 0.001 is 
of greater interest.
For a trial using O’Brien–Fleming-type bounda-
ries, power to achieve p < 0.001 is again very close to 
that of a fixed N = 130-event trial (results not shown). 
Power of the adaptive design was always within 12% 
and 9% of a fixed 130-event trial when NIA = 60 and 
NIA = 89, respectively (Figure 3). For example, for a 
55% effective product, the estimated chance of 
observing p < 0.001 was 81% when NIA = 60 and 84% 
Figure 2. Simulated chance of observing p < 0.025 for fixed 
event and adaptive design trials.
Table 1. Simulated false-positive error rates for adaptivea, fixed 
event total, and traditional IMb design trials
Evidence 
level
Trial design False-positive  
error (95% CI)
p < 0.025 Adaptive NIA = 60 0.0213 (0.0200, 0.0226)
 NIA = 89 0.0233 (0.0220, 0.0246)
 Fixed event N = 90 0.0248 (0.0235, 0.0262)
 N = 130 0.0242 (0.0229, 0.0256)
 Traditional IM Nmax = 130 0.0242 (0.0229, 0.0256)
p < 0.001 Adaptive NIA = 60 0.0008 (0.0006, 0.0011)
 NIA = 89 0.0010 (0.0007, 0.0012)
 Fixed event N = 90 0.0010 (0.0008, 0.0013)
 N = 130 0.0011 (0.0008, 0.0014)
 Traditional IM Nmax = 130 0.0011 (0.0008, 0.0014)
CI: confidence interval; IM: interim monitoring.
aInterim analysis takes place after NIA events. Trial either stops after 90 
events or is expanded to 130 events if (1) conditional power to achieve 
p < 0.001 is at least 50% with expansion and (2) conditional power is no 
more than 95% without expansion.
bIM using Lan–DeMets spending function with O’Brien–Fleming-type 
boundaries to control false-positive error rate at the one-sided 0.001 
level, with interim analyses after 60 and 90 events and maximum num-
ber of events Nmax = 130.
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when NIA = 89, compared to 90% for a fixed N = 130-
event trial. The chance that the adaptive trial expands 
from N1 = 90 to N* = 130 is always less than 50% 
when NIA = 60 and always less than 30% when NIA = 
89 (Figure 4). In contrast, the chance of continuing 
to Nmax = 130 for a trial using O’Brien–Fleming-type 
boundaries increases as effectiveness decreases and is 
essentially 1.0 for all effectiveness levels below 35% 
when not incorporating stopping bounds for futility. 
Although the latter design is more powerful, the 
expected trial size is larger for all evaluated effective-
ness levels below 70% when NIA = 89 and larger for 
all effectiveness levels below 60% when NIA = 60.
By comparing Figure 3 with Figure 4, it is appar-
ent that the chance the adaptive trial expands can be 
nontrivial in scenarios where the overall probability 
of observing p < 0.001 is quite low. For example, 
there is nearly a 30% chance that the adaptive trial 
expands when true effectiveness is 35%, even though 
the overall chance of observing p < 0.001 is less than 
20%. Given that expansion occurs, however, the 
chance of observing p < 0.001 is about 50% or greater 
so long as true effectiveness is at least 35% (Figure 5).
Bias of estimated treatment effects
The estimated bias of the HR estimator was modest 
for the proposed adaptive design, ranging from 
0.025 for true hazard ratios near unity to 0.000 for a 
true hazard ratio of 0.30. Estimated bias for the tra-
ditional trial with O’Brien–Fleming-type boundaries 
was also small, ranging from 0.015 for true hazard 
ratios near unity to −0.005 for a true hazard ratio of 
0.30 (results not shown).
Example
The CAPRISA 004 study, conducted among 889 
HIV-negative women in KwaZulu-Natal, South 
Africa, was the first microbicide trial to demonstrate 
a significant protective effect [19]; randomization to 
a regimen of 1% tenofovir gel was associated with 
an estimated 39% reduction in HIV risk compared 
to an identical placebo regimen (one-sided p = 
0.009; 95% CI: 6%–60%).
Initial design considerations revolved around a 
66-event trial with 80% power to detect a 50% reduc-
tion in risk (a = 0.025), incorporating interim effec-
tiveness analyses after 22 and 44 events. During the 
planning stages, however, the principal investigator 
raised the question which motivated the adaptive 
design considered here: could a trial which looked 
promising near its planned end be expanded in hopes 
of further achieving strength of evidence of two tri-
als. As part of these discussions, the investigator con-
cluded that a trial much larger than 88 events was 
not feasible. This led the statisticians to consider the 
Figure 4. Simulated chance that traditional interim monitoring 
and adaptive design trials continue to 130 events (values in 
parentheses are expected event totals for traditional interim 
monitoring trial, adaptive design with NIA = 60 and adaptive 
design with NIA = 89, respectively).
 
Figure 5. Simulated chance of observing p < 0.001 given that 
adaptive design trial expands from N = 90 events to N = 130 
events (owing to the small chance of expansion, fewer than 
500 replicates contribute to analysis for effectiveness levels 
below 10%).
Figure 3. Simulated chance of observing p < 0.001 for fixed 
event and adaptive design trials.
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operating characteristics of an adaptive design with 
NIA = 44, N1 = 66, N* = 88, and (EL, EU) = (40%, 70%).
Based on these assumptions, the adaptive trial 
could achieve power near that of a fixed N = 88-event 
trial while controlling false-positive error rates near 
0.025 and 0.001 (0.021 and 0.0009, respectively, 
using unadjusted critical values). For example, if the 
microbicide were truly 60% effective, then the adap-
tive design has a simulated 80% chance of observ-
ing p < 0.001, compared to 83% for a fixed 88-event 
trial. The chance that the trial would expand exceeds 
70% for many plausible effect sizes, however, dimin-
ishing the benefits of the adaptive trial compared to 
an N = 88 event study with standard stopping rules. 
Ultimately, a 92-event trial with 90% power to 
detect a 50% reduction in risk with evidence of one 
trial was implemented.
In hindsight, (EL, EU) = (40%, 70%) was too wide an 
interval, requiring expansion when the conditional 
chance of achieving robust evidence was as little as 
16%. Nonetheless, the CAPRISA 004 data can be ana-
lyzed as if the adaptive design had been employed. 
After 44 events, the interim estimate of effectiveness 
was 29.8%, which would not have triggered trial 
expansion. After 66 events, the interim estimate of 
effectiveness was 46.2%, with one-sided p = 0.007. 
Although highly speculative, this suggests that a com-
parable strength of evidence (significant but not suffi-
cient for licensure) might have been achieved in a 
smaller study had the adaptive trial been implemented.
Discussion
An adaptive design was proposed in which a micro-
bicide study with 90% power to detect a 50% reduc-
tion in risk of HIV with evidence of one trial 
(observing one-sided p < 0.025) is expanded to a 
moderately larger number of events, N*, if the 
interim conditional power to achieve a more robust 
evidence threshold (p < 0.001, potentially sufficient 
for licensure) appears promising. Such may be the 
case if the microbicide’s actual effectiveness is mod-
estly higher than 50%.
Asymptotic and simulation results demonstrate 
that, through appropriate choice of expansion criteria, 
the chance that the adaptive design achieves robust evi-
dence of effect can approach that of a fixed a = 0.001 
level trial of size N*, but with the potential for much 
smaller expected study size and while controlling false-
positive error rates at the desired 0.025 and 0.001 levels. 
Group sequential trials using traditional stopping 
boundaries to control the Type I error at a = 0.001 
should provide greater power but at a cost of poten-
tially much larger study sizes, the avoidance of which 
was the motivation to consider alternative designs.
Numerous related designs could be proposed. For 
example, a trial of size N* could be implemented 
which incorporates both interim effectiveness 
boundaries (controlling a = 0.001) and two-stage 
futility boundaries: one stage would trigger a reduc-
tion in size to N1 < N* events if achieving robust 
evidence appears unlikely and a second stage would 
allow the trial to stop entirely if there was little hope 
of achieving even evidence of one trial (p < 0.025). 
Prespecified effectiveness boundaries which control 
the applicable false-positive error rates could likely 
be developed using the types of asymptotic and 
simulation results presented here.
There are a number of important challenges and 
limitations to consider. First, the benefits of the pro-
posed design in terms of expected study size become 
more prominent as the period between when the 
interim analysis which triggers expansion occurs and 
when the trial would otherwise stop gets shorter, 
whereas implementing the trial would get operation-
ally more difficult as this period gets shorter. Second, 
control of false-positive error rates may not be main-
tained using unadjusted tests for studies with differ-
ent design parameters than those considered here. 
Hence, it is essential to assess error rates using simu-
lations or asymptotic results and adjust critical val-
ues using the formula provided as necessary, before 
implementing such a trial. Third, anyone with 
knowledge of the criteria for expansion would gain 
substantial insight into the effectiveness of the prod-
uct if the trial expands; withholding the cumulative 
number of events from all but the Data and Safety 
Monitoring Board (DSMB) and a select few individu-
als could help avoid unintended consequences of 
such knowledge. Fourth, the rules for trial expansion 
are binding once the interim data have been assessed. 
Since the DSMB might choose to stop the trial at the 
interim review due to overwhelming evidence of 
effectiveness, incorporating a highly conservative 
Haybittle–Peto-type boundary at the interim analysis 
may be recommended. Fifth, conditional power con-
siderations presume that effectiveness is constant 
over time. For microbicides, effectiveness is driven 
by participant adherence to the regimen, and a tem-
poral shift in adherence could undermine this 
assumption. In CAPRISA 004 [19], for example, there 
was evidence to suggest that effectiveness dimin-
ished after 18 months of product use, possibly due to 
participant fatigue and reduced adherence to the 
treatment regimen. Sixth, since the trial can stop 
after either N1 or N* events, the final p-value cannot 
be interpreted as the probability of obtaining a more 
extreme result than the one observed. Rather, the 
unadjusted p-value is only used to determine whether 
a particular evidence threshold has been reached. 
Similar limitations hold for CIs; a naïve interval 
computed on the final study data may not have the 
desired coverage. Developing methods of estimating 
p-values and CIs which maintain the desired fre-
quentist interpretations is an area of future research. 
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Finally, the assumption that observing p < 0.001 
would lead regulators to license a product without a 
confirmatory trial may not be justifiable in settings 
that do not involve outcomes associated with high 
morbidity or mortality like HIV. Even here, regula-
tors or public health programs may require addi-
tional studies to gather sufficient safety data.
Despite the challenges, adaptive designs like the 
one proposed should be considered when there is 
little preliminary evidence of effectiveness to inform 
the size of a Phase 3 trial. Such evidence is generally 
not available to microbicide researchers owing to 
the absence of surrogate outcomes to inform prod-
uct effectiveness in modest-sized Phase 2 trials.
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Appendix 1
The conditional power to achieve p < α if the trial is 
expanded to N* > N1 events was computed as
1
/
/ / / /ln ln
N N














i i i i ik* 4
(3)
where SE is the standard error of the logged 
interim HR estimate (HRIA) from a proportional 
hazards regression model, NIA is the number of 
events at the time of the interim analysis, N* is 
the number of events if the trial is allowed to 
expand, and HRalt is the hazard ratio under the 
alternative hypothesis (HRalt = HRIA in power 
simulations and HRalt = 1 when assessing false-
positive error rates). Likewise, the conditional 
power to achieve evidence of effect if the trial is 
not expanded is computed as
1
/
/ / / /ln ln
N N
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(4)
The lower and upper bounds on the interim esti-
mate of effectiveness which trigger expansion of the 
study (EL, EU) may be computed by iteratively solv-
ing Equations (3) and (4) for any chosen conditional 
power values, assuming 4/SE NIA=  and effective-
ness = 1 − HRIA.
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